Dynavax Technologies Corporation (DVAX) : 3 analysts are covering Dynavax Technologies Corporation (DVAX) and their average rating on the stock is 1.67, which is read as a Buy. 2 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 4, which recommends a Sell affirms that they expect a large upside in the stock from the current levels. A total of 1 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Dynavax Technologies Corporation (DVAX) has been rated by 3 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $45 and the lowest price target forecast is $17. The average forecast of all the analysts is $35.67 and the expected standard deviation is $16.17.
Shares of Dynavax Technologies Corporation rose by 5.71% in the last five trading days and 12.33% for the last 4 weeks. Dynavax Technologies Corporation is up 4.53% in the last 3-month period. Year-to-Date the stock performance stands at -30.26%. Dynavax Technologies Corporation (NASDAQ:DVAX): stock turned positive on Tuesday. Though the stock opened at $16.77, the bulls momentum made the stock top out at $16.98 level for the day. The stock recorded a low of $16.52 and closed the trading day at $16.85, in the green by 0.66%. The total traded volume for the day was 481,931. The stock had closed at $16.74 in the previous days trading.
Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are organized under three areas of focus: vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases. The Companys pipeline of product candidates includes HEPLISAV-B, an investigational adult hepatitis B vaccine, is in Phase III clinical trials; SD-101, a cancer immunotherapy candidate, is in Phase I/II clinical trials; AZD1419, a candidate drug for asthma, is in Phase II clinical trials planning; DV1179 is an inhibitor of TLR 7 and TLR 9 for autoimmune and inflammatory diseases, is in Phase I clinical trials. DV230-Nanoparticle is a second generation adjuvant. DV230-Nanoparticle is in preclinical stage.